Article Details
Retrieved on: 2021-06-07 19:07:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
AstraZeneca's Calquence displayed a better heart safety profile in a head-to-head clinical trial against Johnson & Johnson and AbbVie's Imbruvica.
Article found on: www.fiercepharma.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here